london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Posters

Intravitreal ranibizumab treatment for ocular pathology other than neovascular age-related macular degeneration

Poster Details

First Author: P.Kalouda GREECE

Co Author(s):    E. Kanonidou   C. Skatharoudi   I. Zampros   E. Zopounidou   D. Balatsoukas      0   0 0   0 0   0 0   0 0

Abstract Details



Purpose:

To evaluate the efficacy and safety of intravitreal ranibizumab monotherapy in patients with diabetic macular edema (DME) and patients with macular edema after retinal vein occlusion (RVO).

Setting:

Department of Ophthalmology, ‘’Hippokrateion’’ General Hospital of Thessaloniki, Thessaloniki, Greece.

Methods:

Retrospective analysis of 26 eyes (18 patients) (9 male, 9 female) with DME receiving ranibizumab injections with a mean age of 70.8 years old (SD: 10.8 years) and a total of 16 eyes (16 patients) (5 male, 11 female) with macular edema after branch RVO (BRVO) (8 eyes) and central RVO (CRVO) (8 eyes)) receiving ranibizumab injections with a mean age of 63.7 years old (SD: 7.7 years). Ocular pathology was confirmed by fluorescein angiography and optical coherence tomography. Patients meeting prespecified criteria received 0.5 mg of ranibizumab on an as-needed (pro re nata [PRN]) regimen. Follow up was held on a monthly basis. Best-corrected visual acuity examination (BCVA) and central retinal thickness (CRT) measurements were evaluated during the follow up period.

Results:

The mean follow up period was 12.2 months (SD: 12 months) for patients with DME and 6.8 months (SD: 6.6 months) for patients with macular edema after RVO. In terms of DME the mean number of injections/patient was 2.7 (SD: 2.3 injections), the mean BCVA was 0.79 logMAR (SD: 0.27 logMAR) at baseline, improved to 0.66 logMAR (SD: 0.3 logMAR) at final examination (p=0.08). Regarding RVO, the mean number of injections/patient was 1.8 (SD: 1.1 injections), the mean BCVA was 0.62 logMAR (SD: 0.32 logMAR) at baseline, improved to 0.42 logMAR (SD: 0.37 logMAR) at final examination (p<0.05). Specifically, changes in visual acuity in patients with DME were found as follows: unchanged 46.15% (12 eyes), improved 46.15% (12 eyes) and deteriorated 7.69% (2 eyes), whereas in patients with RVO were: unchanged 12.5% (2 eyes), improved 87.5% (14 eyes) and deteriorated 0% (0 eyes). No injection complications or drug related side effects were recorded.

Conclusions:

After treatment with intravitreal injections of ranibizumab in eyes with diabetic macular edema and macular edema after retinal vein occlusion, a substantial number of the studied patients showed an improvement in visual acuity values with no ocular and systemic associated side-effects. Singularly, the effect that ranibizumab provided on RVO was rapid even after one single dose of injection.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy